spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

Published quarterly, European Pharmaceutical Contractor (EPC) covers the essential contract research issues between pharma companies and their CRO partners. The title, which is integrated within International Clinical Trials (ICT) magazine, offers a strategic view of the drug development industry Ė giving its pharma, biotech and CRO readership expert insight and analysis on the sponsor-service provider landscape.

EPC focuses on key trends, concerns and developments in contract research operations across the drug development spectrum, from preclinical to post-marketing. It explores the shifting collaborative needs and practical implications for sponsors and their contract partners, with the emphasis on building and managing effective collaborations.

Prompted by the synergies between outsourcing and trial operations, EPC joined forces with sister brand ICT in late-2015, in a move that brings added value to both brands. With EPC now an inserted edition within ICT, industry practitioners across these complementary subject areas now have unrivalled access to a wealth of shared views and analyses.

 

For further information please contact:

Advertising
Nick Matthews

Editorial
Thanh Thanh Lam

We're also on Twitter! Follow us @EPCmagazine

The latest digital edition of EPC can be viewed here
 

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


epc
 
 
Featured in this issue
Data Management & IT Solutions
Biostatistics

SAS and R Team in Clinical Research


To either prove or disprove stated hypotheses, it is necessary to carry out statistical analyses and collect data. KCRís Adrian Olszewski introduces two reliable packages to support evidencebased research on drugs.


Legal & Regulatory
ICH E6 (R2) Addendum

Game Changer


The new ICH guidance will be implemented in November 2016, which will have a profound effect on the management of clinical trials. Nick Neri at ERT outlines some of the steps that pharma companies need to take in order to remain compliant.
  Legal & Regulatory
Data De-Identification

Protecting Patient Identities


As organisations are required to become more transparent in their studies, the identities of patients are being put at risk. d-Wiseís Chris Olinger comments on new guidelines trying to alleviate this problem.

spacer



Published quarterly in
February, May,
August and November


 

Industry Events

9th Adaptive Designs in Clinical Trials

3-4 April 2017, Copthorne Tara Hotel, London, UK

SMiís annual conference on Adaptive Designs in Clinical Trials will return to London on 3rd & 4th April 2017. Now running for nearly a decade, this unmissable event will gather a senior audience of experts to discuss and deliberate recent innovations and successes in this exciting field of science.
More info >>

 
News and Press Releases

Oxford Genetics secures £1.61m Innovate UK grant to establish next-generation bioproduction technologies


More info >>

air transport logo

 

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement